Our Safety‑First Gene‑Therapy Platform
Vecgen is committed to providing cutting-edge safety solutions for gene therapy. Contact us today to explore our innovative services.
Candidate Screening
Evaluate toxicity of investigational
products
QC Manufacturing
Qualify batch-to-batch variation
Patients
Inform clinical trials and post-administration patient monitoring
About Our Visionary Team
At Vecgen, we are driven by a passion for excellence and a dedication to advancing gene therapy safety. Our team of scientists and industry veterans combine deep scientific expertise with innovative technologies to deliver immunotoxicity services for gene therapy companies.
With a focus on safety, efficacy, and regulatory readiness, we partner with organizations at every stage of development—from preclinical studies to clinical trials and beyond. By working hand-in-hand with pharmaceutical companies, physicians, and patient advocacy groups and clinical collaborators, we aim to bring hope to patients in need by accelerating the future of safer gene therapy.
How It Works
Discover & Profile
Predict & Optimize
Validate Safely
Report & Monitor
Vecgen's novel immunotoxicity assay allows gene therapy developers to screen among investigational products, identifying critical cellular readouts in human cells and allowing them to move forward with safer pre-clinical candidates. Our technology also enables exploration of patient-specific immune signatures, allowing physicians to make informed point-of-care decisions.
Advancing Gene Therapy Safety
Our experts are ready to help you navigate the complexities of gene therapy development with confidence.
Safety Overview
About Us
Team
How It Works
Contact
Privacy Policy
Terms and Conditions
© 2025 VECGEN, All rights reserved.